Woodline Partners and RA Capital Management led a $89m Series B round in Frontier Medicines. Additional investors included Deerfield Management Company, Deep Track Capital, ArrowMark Partners, Driehaus Capital Management, Sphera Healthcare, DCVC, Droia Ventures, and MPM Capital. “We welcome the new group of investors who participated in this financing and appreciate the confidence they have shown in our highly differentiated scientific approach. Between the substantial protein degradation partnership with AbbVie announced at the end of last year and this financing round, we have significantly strengthened our resources to deliver on our vision of developing breakthrough medicines for patients," Chris Varma, Frontier Medicines Chairman, CEO, and Co-Founder.